Mode
Text Size
Log in / Sign up
N/A Completed N=36 Treatment

The Clinical Efficacy And Safety Of SkinStylus Microneedling System

Cicatrix, Hypertrophic
Source: ClinicalTrials.gov NCT03366194 ↗
Enrolled (actual)
36
Serious AEs
0.0%
Results posted
May 2022
Primary outcomePrimary: Number of Participants With Improvement Assessed Using the VAS Scar Scoring System — 22 Participants

Summary

The purpose of the trial is to provide objective evidence the SkinStylus may be used safely and effectively for the treatment of ventral torso hypertrophic scars.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Improvement Assessed Using the VAS Scar Scoring System
22
SECONDARY
Number of Patients Self-Reporting Improvement Using the Validated Self-Assessed Scar Improvement Scale Satisfaction Survey
28

Eligibility Criteria

Inclusion Criteria

  • at least 23 years old
  • shall have at least one suitable ventral torso hypertropic scar of sufficient length that it may be easily visualized in two halfs.
  • The scar(s) must present along a flat surface suitable for application of the SkinStylus® device and consistent medical photography.

Exclusion Criteria

  • Pregnancy or chance of pregnancy
  • Currently taking Coumadin/Warfarin® or heparin
  • Diagnosis of any type of bleeding disorder
  • Any history of keloid formation
  • Lidocaine, tetracaine, prilocaine, bupivacaine, or benzocaine hypersensitivity
  • Diagnosis of mental disorders requiring inpatient treatment
  • Presence of metal implants around the proposed treatment areas
  • Diagnosis of any undefined wasting disease (Cachexia for example)
  • Diagnosis of an active infection in the treatment area other than mild acne
  • Diagnosis of the presence of tumors or those who are being treated by chemotherapy or radiation therapy
  • Diagnosis of severe cardiovascular and cerebrovascular disease
  • Diagnosis of renal failure
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03366194). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search